Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 19/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.58 |
| ▸ | KIT | P10721 | 9/20 | 0.58 |
| ▸ | PDGFRA | P16234 | 9/20 | 0.58 |
| ▸ | FLT3 | P36888 | 9/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PI4KA | P42356 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676922 | 0.94 | CSF1R (0.60) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL19415443 | 0.94 | CSF1R (0.60) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL19415532 | 0.93 | CSF1R (0.59) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2676934 | 0.93 | CSF1R (0.59) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2677440 | 0.92 | CSF1R (0.56) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL19415499 | 0.92 | CSF1R (0.56) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL19415500 | 0.92 | CSF1R (0.55) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2676140 | 0.92 | CSF1R (0.55) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2676787 | 0.92 | CSF1R (0.56) | CSF1RPDGFRBKITPDGFRAFLT3 | |
| SCHEMBL2676799 | 0.91 | CSF1R (0.55) | CSF1RPDGFRBKITPDGFRAFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553854-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-06-30 | — | — | US | claimed |
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| EP-2010528-B1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG (CH) | 2017-10-04 | — | — | EP | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-8710048-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2014-04-29 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8173689-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173689-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173689-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-20100280006-A1 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS AG (CH) | 2010-11-04 | — | — | US | disclosed |
| US-7553854-B2 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | NOVARTIS AG | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225861-A1 | 6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods of Inhibiting CSF-1R Signaling | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRB 421/4885KIT 275/4885 |
| US-20100280006-A1 | 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRB 421/4885KIT 275/4885 |
| US-20080045528-A1 | 6-O-SUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AND METHODS OF INHIBITING CSF-1R SIGNALING | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRB 421/4885KIT 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.